Hahn Mark W

CFO Mark W Hahn sold 208,912 shares of VRNA at $13.14 on 2025-08-01; stock up 15.2% in 30 days.

Mark W Hahn, Chief Financial Officer of Verona Pharma plc, sold 208,912 shares (208.9K shares) at $13.14 on 2025-08-01, reducing his holdings by 1.6% to 12,464,968 shares (12.46M shares). The stock has since appreciated significantly—up 15.2% in 30 days and 52.4% in 90 days since the sale, indicating this transaction was poorly timed relative to subsequent price performance. Notably, his prior VRNA trade on 2025-05-02 showed similar post-sale strength, with a 90-day return of +1055.6%, and his cross-ticker track record demonstrates that stock prices have risen an average of +1158.2% in the 90 days following his sales (90d well-timed rate 0.00%), further underscoring a consistent pattern of selling before rallies. The company remains unprofitable with a net loss of $16,319,000.00 ($-16.3M) in its most recent quarter and full-year period, creating a context in which the CFO's sales deserve monitoring even as they coincide with substantial stock gains rather than declines.

CFO Hahn Mark W sold 400,000 shares of VRNA at $11.40; stock now trades at $92.20, up 37.1% in 30 days

Mark W Hahn, CFO of Verona Pharma, sold 400,000 shares (400.0K shares) at $11.40 on 2025-06-11 for $4,560,360.00 ($4.6M), reducing his holdings to 12,278,992 shares (12.28M shares). The stock has appreciated dramatically since the transaction date, reaching $92.20 (current price) with a 30-day return of +37.1% and 90-day return of +50.2%, placing the price -0.3% from its 52-week high of $92.50. At the same ticker (VRNA), Hahn's prior two measurable sales (on 2025-05-02 and 2025-05-01) both generated positive 30-day returns of +792.9% and +807.2% respectively, indicating his prior VRNA sales preceded sharp gains, not declines. The company is unprofitable (net income $-16,319,000.00 ($-16.3M)) with latest quarterly revenue of $76,256,000.00 ($76.3M), and the stock's 50% run-up over 90 days contrasts sharply with the CFO's simultaneous reduction of his own stake.

Verona Pharma CFO Mark W Hahn sells 400,000 shares in 3 trades (May 27–29) for $3,733,944.47; stock rises to $77.49 post-sale.

Mark W Hahn, Chief Financial Officer of Verona Pharma, executed 3 separate sales totaling 400,000 shares for $3,733,944.47 (blended average $9.33) over three consecutive trading days. The stock has since appreciated significantly, trading at a 52-week high of $77.49, representing a sharp disconnect between the transaction prices ($9.33) and current valuation. Notably, his cross-ticker track record shows a well-timed sell rate of 0.00% across 20 prior sales, with an average 90-day return post-sale of +1162.7%—indicating his prior sales have been consistently poorly timed, as stocks typically rose after his exits. At Verona specifically, his one prior measurable 90-day outcome (December 2024 sale) showed +1211.0% return, reinforcing the pattern. The company remains unprofitable with net income of $-16,319,000.00 against revenue of $76,256,000.00, adding context to the divergence between insider action and market momentum.

CFO Mark Hahn sold 587,008 shares at avg $9.05 for $5.3M; stock now at $72.25, +34% in 30d

Mark Hahn, Chief Financial Officer of Verona Pharma plc, executed 3 separate sales totaling 587,008 shares for $5,311,479.00 on 2025-05-01 and 2025-05-02, at a blended average price of $9.05. His post-transaction holdings remain substantial at 13,078,992 shares. The current stock price of $72.25 represents a 30-day return of +34.0% since these transactions, and the stock is now -1.3% from its 52-week high of $73.22. Notably, his prior sales at VRNA (4 trades measurable at 90 days) generated average returns of +1103.0%, yet 0 of 4 prior sales were well-timed by the 90-day mark—the stock rose substantially after each sale. The company remains unprofitable, with most recent quarterly net income of $-16,319,000.00 against revenue of $76,256,000.00, yet the market capitalization has expanded to $49.2B.

CFO Mark W Hahn sold 90,360 shares of Verona Pharma (VRNA) at $8.98 on 2025-04-29; stock now at $72.26.

Hahn sold 90,360 shares at $8.98, reducing holdings by 0.7% to 13,466,000 shares while the stock has appreciated 23.4% over the past 30 days and 26.1% over 90 days. His cross-ticker track record shows 20 prior sells with an average 90-day return of +1125.5% and a well-timed rate of 0.00%, indicating his prior sales have generally occurred before upward price movements rather than declines. At VRNA specifically, his 3 measurable prior sells (all in early December 2024) were each followed by gains of 830%+ over 30 days and 1211%+ over 90 days, with zero of those sells being well-timed (a 90-day well-timed rate of 0 of 3). The company is unprofitable with a net income of $-16,319,000.00 against revenue of $76,256,000.00, yet the stock is trading near its 52-week high of $73.22 at $72.26. The timing and magnitude of prior underperformance in predicting VRNA declines, combined with the stock's strong recent momentum and the company's negative earnings, suggests this transaction does not fit a pattern of prescient exit timing.

CFO Mark W Hahn sold 881,960 shares ($4.4M) at $5.01 avg over 3 days as stock trades at $40.50

Hahn Mark W, Chief Financial Officer of Verona Pharma plc, executed 3 separate sales totaling 881,960 shares for $4,415,451.85 across December 4–6, 2024, at a blended average price of $5.01. The current stock price of $40.50 is 708% above the transaction prices, indicating a dramatic disconnect between when the CFO sold and the stock's subsequent rally. The company is unprofitable with a net income of $-42,962,000.00 in its latest fiscal year and generated only $5,624,000.00 in quarterly revenue. Prior trades at this ticker show a pattern of poorly-timed sales: Hahn sold on November 1 and November 4, 2024, and both positions generated +805.6% and +808.2% 30-day returns respectively, meaning the stock rallied sharply after he sold. The 0 of 0 well-timed rate on VRNA prior sells confirms that Hahn has not successfully predicted downturns at this ticker; instead, his sales have preceded gains.

CFO Hahn sells 113,240 shares across 3 trades (Nov–Dec 2024) for $566,821.84 at $5.01 blended avg; stock now $39.11.

Hahn Mark W, Chief Financial Officer of Verona Pharma plc, executed 3 separate sales totaling 113,240 shares for $566,821.84 at a blended average price of $5.01 between November 27 and December 2, 2024. His post-transaction holdings remain substantial at 14,175,696 shares, representing a -0.8% reduction from pre-transaction levels. The current stock price of $39.11 is 7.8× the transaction prices, a dramatic divergence that reflects either significant upside movement post-sale or a structural pricing discrepancy. At VRNA specifically, his 5 prior trades showed very strong 30-day returns (+763.4% to +805.6%), yet the company reports negative fundamentals: a most recent quarter revenue of $5,624,000.00 against a net income loss of $-42,962,000.00, with annual revenue growth of -100.0%. This combination—large insider sales at low absolute prices concurrent with massive losses and revenue collapse—warrants examination of whether the transaction prices reflect near-term conditions that differ materially from current market valuation.

CFO Mark Hahn sold 129,672 shares of VRNA for $568,386.66 across two transactions on Nov 1–4 at blended avg $4.38, while stock at $38.39 (current).

Mark Hahn, CFO of Verona Pharma, executed 2 separate sales totaling 129,672 shares for $568,386.66 at a blended average price of $4.38 on November 1–4, 2024. The current stock price of $38.39 stands dramatically higher than his transaction prices, suggesting these sales were executed at a significant discount to the stock's recent peak and 52-week high. His cross-ticker track record shows an average 90-day return of +494.3% after sells with a well-timed rate of 0.00%, indicating a historical pattern of poorly timed exits that missed subsequent gains. At VRNA specifically, his 5 prior trades within the past two weeks (October 18–25) all preceded unmeasurable outcomes, establishing a recent pattern of frequent dispositions. Post-transaction, he retains 14,293,736 shares (14.29M), representing a -0.9% reduction in holdings from 14,423,408 shares (14.42M), suggesting these sales are relatively modest reductions to a substantial continuing position. The company reported quarterly revenue of $5,624,000 ($5.6M) with net income of $-42,962,000 ($-43.0M) and full-year revenue growth of -100.0%, indicating severe operational and financial headwinds that may warrant scrutiny of the CFO's trading pattern in context of deteriorating fundamentals.

CFO Hahn sells 144,560 shares at $4.38 across 2 transactions (10/24–10/25); stock up 19.8% in 30 days.

Chief Financial Officer Mark W. Hahn sold 144,560 shares totaling $632,760.99 at a blended average price of $4.38 on October 24–25, 2024, reducing holdings by 1.0% to 13.67M shares. The current market price is $33.86, reflecting a 52-week range of $11.48–$34.97 and a 30-day gain of 19.8%, placing the transaction price substantially below current levels. Notably, Hahn has executed five separate sales at Verona Pharma within the prior two weeks (October 18, 21, 22, and now 24–25), suggesting a deliberate pattern of share reduction during a period of strong price appreciation. His cross-ticker track record shows 10 prior sells with an average 90-day return of 494.3% but a 0.00% well-timed rate, indicating such sales have historically been followed by further gains rather than declines, though the company's current fundamentals show zero revenue in the latest quarter and a net loss of $70.8M, warranting examination of whether the selling pattern reflects broader operational or capital allocation concerns.

CFO Mark W Hahn sold 525,768 shares at $4.38 across 3 transactions (Oct 18-22), reducing stake by 3.7% while stock at 52-week high.

Mark W Hahn, CFO of Verona Pharma, executed 3 separate sales totaling 525,768 shares for $2,303,772.76 between October 18-22, 2024, at a blended average price of $4.38, reducing his holdings from 14,339,688 to 13,813,920 shares. The timing is noteworthy: the stock currently trades at $34.87, near its 52-week high of $34.97, representing substantial appreciation from the $4.38 sale price. His prior trades at VRNA (5 previous sales) have produced notably strong 30-day returns (ranging from +680.8% to +863.3%), though only 1 of his 1 measurable 90-day outcomes at this ticker was well-timed, suggesting the stock tends to continue rising after his sales rather than declining. The company remains unprofitable with $-70,835,000.00 net income and zero revenue in the latest quarter, adding fundamental context to the selling activity.